Inflammation is a key element of AD, and plasma glial fibrillary acidic protein (GFAP), YKL 40, soluble triggering receptor expressed on myeloid cell 2 (sTREM2), and monocyte chemotactic protein-1 (MCP-1) measured in the CSF have promise as target engagement biomarkers for anti-inflammatory agents [40,41,42,43,44]. The gene discussed is GFAP; the disease is Alzheimer disease.